| Code | CSB-MP021303HU |
| Abbreviation | Recombinant Human SIGLEC9 protein, partial (Active) |
| MSDS | |
| Size | $138 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
SIGLEC9 mediates immune inhibitory signaling through recognition of sialylated glycans, making it a critical checkpoint in myeloid cell regulation and tumor immune evasion. This recombinant extracellular domain (aa 18–348) demonstrates quantifiable antibody-binding activity with an EC50 of 1.033–1.429 ng/mL in functional ELISA, providing a validated reagent for therapeutic antibody epitope mapping, competitive inhibition screening, and blocking antibody development targeting SIGLEC9-sialoglycan interactions. Mammalian expression preserves the native glycosylation and disulfide architecture essential for authentic ligand recognition, supporting high-confidence data in surface plasmon resonance affinity characterization, biolayer interferometry kinetic studies, and small-molecule inhibitor screening campaigns. The protein meets the purity and endotoxin criteria typical for cell-based assays (>95% pure, <1.0 EU/μg), enabling its use as a positive control in binding platforms and in immune checkpoint research focused on myeloid immunomodulation.
There are currently no reviews for this product.